Clinical

Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.

The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.

Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.

Rachel Dalthorp, MD, discusses how zuranolone (Zurzuvae) can improve postpartum depression when compared with previous treatment approaches.

Results show that cognitive decline, combined with factors like smoking, obesity, and chronic health conditions, sharply increased the likelihood of premature death among patients with schizophrenia.

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.

Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect profile that is consistent with high-dose steroid use in other conditions, according to a meta-study that analyzed immunosuppressive protocols.

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic cough in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Cases of atrial arrhythmia in patients with Duchenne muscular dystrophy (DMD) are common but lack a standard solution, and more long-term data on the management of arrhythmias in DMD are needed.

Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.

A substantial overall survival (OS) disparity by race and ethnicity was found in patients with colorectal cancer (CRC), with socioeconomic status and tumor molecular features largely contributing to the difference in OS.

Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.

MYL-1701P displayed similar efficacy, safety, and immunogenicity when compared with reference aflibercept to treat diabetic macular edema.

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.

The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant chemotherapy alone in high-risk early-stage triple-negative breast cancer (TNBC).

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).

A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.